In a similar manner, Sasaki and colleagues combined electrical pacing with CPVT- and control-hiPSC-CMs to validate S107, a drug that stabilizes the closed state of the RYR2, as potential therapeutic agent for CPVT1 [131]. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.